Get access

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

Authors

  • Harald Mischak

    Corresponding author
    1. Mosaiques Diagnostics, Hannover, Germany
    • BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
    Search for more papers by this author
    • Member of the European Kidney and Urine Proteomics COST Action (EuroKUP).


Correspondence: Dr. Harald Mischak, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Avenue, Glasgow G12 8TA, UK

E-mail: Harald.Mischak@glasgow.ac.uk

Fax: +44-141-330-1689

Abstract

Clinical proteomics is defined as application of proteome analysis aiming at improving the current clinical situation. As such, the success of clinical proteomics should be assessed based on the clinical impact following implementation of the findings. While we have experienced significant technological advancements in mass spectrometry in the last years, based on the above measure, this has not at all resulted in similar advancements in clinical proteomics. Although a large number of proteomic biomarkers have been described, most of them were not subsequently validated, and certainly have had no impact in clinical decision making as yet. Under the current conditions, it appears likely that the situation will not change significantly: we will be flooded by reports on biomarkers, but not see any implementation. In this article, some key issues in proteomic biomarker research are pinpointed, based on the experience with CE-MS, likely also holding true for biomarkers resulting from other analysis domains.

Ancillary